[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Immuneering "Were proud to be a 2025 #ScripAwards finalist as Best Oncology R&D Advance for our Phase 2a trial of atebimetinib in pancreatic cancer This honor reflects our commitment to advancing new treatments that aim to help patients live longer & feel better. #Oncology #CancerResearch"
X Link @Immuneering 2025-10-07T16:00Z XXX followers, XXX engagements

"$IMRX and @BenZeskind were honored to join @bradloncar and @BiotechTV live from the NYSE to discuss our latest progress in oncology including promising pancreatic cancer data and our deep cyclic inhibitors. Watch the full video here:"
X Link @Immuneering 2025-10-10T15:34Z XXX followers, XXX engagements

"Meet us in Vienna during #BIOEurope taking place Nov 3-5 Our CBO E.B. Brakewood will be onsite to meet with global business leaders and industry experts in the biotech & pharma fields. Learn more about $IMRX and our pipeline:"
X Link @Immuneering 2025-10-13T16:00Z XXX followers, XXX engagements

"Our clinical data featured in @TargetedOnc highlight the potential of our investigational therapy atebimetinib in combination with chemotherapy to help address pancreatic cancer an area of urgent unmet need"
X Link @Immuneering 2025-10-09T16:00Z XXX followers, XXX engagements

"ICYMI: $IMRX ended Sept. with strong momentum: XX% 9-month survival in 1L pancreatic cancer (atebimetinib + mGnP) and a $200M financing including $25M from Sanofi. Webcast replay:"
X Link @Immuneering 2025-10-15T15:20Z XXX followers, XXX engagements